Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Methocarbamol 750 mg film-coated tablets

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Methocarbamol may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Methocarbamol

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

•

Other medicines and Methocarbamol If you are taking any of the following medicines, you should tell your doctor or pharmacist as Methocarbamol may interact with them:

  • Barbiturates which can be taken for epilepsy or to help you sleep.
  • Appetite suppressants to help you lose weight.
  • Medicines for stomach upsets or sea-sickness (anticholinergics).
  • Psychotropic drugs for the treatment of anxiety, depression or other mental illnesses.
  • Pyridostigmine bromide, which is used for myasthenia gravis. You should not take methocarbamol if you have pathological muscle weakness (myasthenia gravis).
  • If you are due to have anaesthetic for any reason, tell your doctor or dentist that you are taking Methocarbamol.

are allergic to methocarbamol, or have had any problems in the past with medicines containing methocarbamol are allergic to any of the other ingredients of this medicine (listed in section 6) have ever suffered any brain damage or coma suffer from epilepsy or convulsions suffer from muscle weakness (a disease called myasthenia gravis)

Warnings and precautions Talk to your doctor or pharmacist before taking Methocarbamol. Tell your doctor or pharmacist before taking Methocarbamol if you:

  • are pregnant or thinking of becoming pregnant
  • are breastfeeding
  • have, or have had, any kidney or liver problems
  • are having any medical investigations or tests as Methocarbamol could interfere with the results. Tell your doctor that you are taking Methocarbamol before you have the test. Children and adolescents This medicinal product is not intended for use in children and adolescents as safety and efficacy in these patient groups have not been established.

Information on Sodium content This medicine contains less than 1 mmol sodium (23 mg) per filmcoated tablet, that is to say essentially 'sodium-free'.

What you need to know before you take it

e Methocarbamol Do not take Methocarbamol if you:

• • • •

Methocarbamol with alcohol Consumption of alcohol during methocarbamol treatment may potentiate the effect of the medicine. Do not drink alcohol while you are taking methocarbamol. Pregnancy, breast-feeding and fertility Pregnancy There is no experience available concerning the use of methocarbamol during pregnancy. The potential risk to humans is not known. You should not take methocarbamol during pregnancy.

How to take it

Methocarbamol Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Adults: Take TWO tablets with a little water, FOUR times a day. Sometimes a lower dose may be sufficient. You should spread the doses as evenly as possible over a 24-hour period. Elderly: older patients may only need half the usual dose to give the same relief from the pain and muscle spasms. Children: These tablets should not be given to children Liver impairment: you may need a longer interval between taking the tablets if you have liver disease. You should always follow your doctor's instructions carefully. These tablets are for short-term treatment. Take them for as long as your doctor has recommended, or until you no longer need them to ease the pain. Return any unused tablets to your pharmacist.

Black A/s: 210 x 300 mm

Initiator Artist:

Component

Item Code

Date & Time

Leaflet

P1540169

06.10.2025 & 9:15 AM Reviewed / Approved by

Customer / Country

Version No.

Reason Of Issue

Milpham_Unit-15

01

Revision

Ramesh P

Dimensions

No. of Colours : 01

Jaya Durga

210 x 300 mm

Packaging Development Team Leader

Product Name Methocarbamol

40169

Additional Information : Supersede Item Code: P1536211

Sign / Date

Method of administration Methocarbamol is for oral use. Swallow the film-coated tablets with plenty of water. The film-coated tablets should be taken for as long as the symptoms of muscle tightness persist, but no longer than 30 days. If you take more Methocarbamol than you should Contact your doctor immediately, go or take the person to the Accident and Emergency Department of your local hospital. Always take the bottle of Methocarbamol with you, even if it is empty. If you forget to take Methocarbamol

Possible side effects

you can help provide more information on the safety of this medicine.

Marketing Authorisation Holder Milpharm Limited 1 Roundwood Avenue Stockley Park, Uxbridge UB11 1AF United Kingdom Manufacturer APL Swift Services (Malta) Limited HF26, Hal Far Industrial Estate, Hal Far, Birzebbugia, BBG 3000, Malta Or Milpharm Limited 1 Roundwood Avenue Stockley Park, Uxbridge UB11 1AF United Kingdom Or Generis Farmacêutica, S.A., Rua João de Deus, n.o 19, Venda Nova, 2700-487 Amadora, Portugal This leaflet was last revised in 10/2025.

How to store it

Methocarbamol Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and bottle after EXP. The first two numbers indicate the month; the last four numbers indicate the year. The expiry date refers to the last date of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

P1540169

This medicine does not require any special storage conditions

Contents of the pack and other information

What Methocarbamol contains The active substance is methocarbamol Each film-coated tablet contains 750 mg methocarbamol The other ingredients are: Tablet core: maize starch, sodium starch glycolate (Type – A), povidone (K-30), sodium laurilsulfate, talc and magnesium stearate Tablet coat: hypromellose 2910 (6mPas), titanium dioxide and macrogol 400.

Take your normal dose when you remember. Always leave at least 4 hours before taking any more tablets. DO NOT TAKE A DOUBLE DOSE OF TABLETS TO MAKE UP FOR A MISSED DOSE.

What Methocarbamol looks like and contents of the pack Methocarbamol 750 mg film-coated tablets are white, film coated, capsule shaped biconvex tablet, debossed with 'METT' on one side and '750' on the other side.

4. Possible side effects

Methocarbamol 750 mg film-coated tablets are supplied in a white opaque round HDPE container.

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Pack sizes: 100 film-coated tablets.

If you notice any of the following rare symptoms, you should STOP taking your tablets and tell your doctor immediately:

  • confusion, convulsions, fits, and rash or swelling of the face or neck and shortness of breath which may be a sign of an allergy Rare (may affect up to 1 in 1,000 people): Conjunctivitis, headache, dizziness, metallic taste, decreased blood pressure, nasal congestion, angioedema (acute-onset swelling of parts of the tissue and skin), rash, itching, nettle rash (urticaria), fever Very rare (may affect up to 1 in 10,000 people): Anaphylactic reactions (allergic hypersensitivity reactions), loss of appetite, restlessness, anxiety, confusion, fainting, involuntary eye movement, giddiness, trembling, seizures, impaired vision, slow heart beat, hot flushes, retching (nausea) and vomiting Not known (frequency cannot be estimated from the available data): Drowsiness, disturbance of coordination Reporting of side effects If your child gets any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting

Frequently asked questions about Methocarbamol 750 mg film-coated tablets

How do I take Methocarbamol 750 mg film-coated tablets?

Methocarbamol 750 mg film-coated tablets comes as tablet containing 750mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Methocarbamol 750 mg film-coated tablets?

The active substance in Methocarbamol 750 mg film-coated tablets is methocarbamol.

Are there equivalent medicines to Methocarbamol 750 mg film-coated tablets?

Medicines with the same active substance, strength and form include: Robaxin-750, 750 mg Film-coated Tablets, Methocarbamol 750 mg film coated-Tablet, Methocarbamol 750 mg tablets. In total there are 5 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Methocarbamol 750 mg film-coated tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Methocarbamol 750 mg film-coated tablets without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Methocarbamol (9 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Symptomatic treatment of painful muscular tension, especially in the lower back (lumbago)

Methocarbamol is indicated in adults

4.2. Posology and method of administration

Posology

Adults: The usual dose is 2 tablets four times daily but therapeutic response has been achieved with doses as low as 1 tablet three times daily.

Elderly: Half the maximum dose or less may be sufficient to produce a therapeutic response.

Paediatric population

Not recommended.

Hepatically impaired

In patients with chronic hepatic disease the elimination half-life may be prolonged. Therefore, consideration should be given to increasing the dose interval.

Method of administration

For oral use.

Take the film-coated tablets with sufficient water.

4.3. Contraindications

Hypersensitivity to methocarbamol or to any of the excipients listed in section 6.1.

• Coma or pre-coma states

• Central nervous system disorders

• Myasthenia gravis

• Patients with a tendency to epileptic cramps

4.4. Special warnings and precautions for use

Methocarbamol should be used with caution in patients with renal and hepatic insufficiency.

This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially 'sodium-free'.

Interference with laboratory tests

Methocarbamol may cause colour interference in certain screening tests for 5-hydroxyindolacetic acid (5-HIAA) and vanillylmandelic acid (VMA)

4.5. Interaction with other medicinal products and other forms of interaction

If methocarbamol is used concomitantly with centrally acting drugs such as barbiturates, opioids and appetite suppressants, the effects can be mutually enhanced.

The consumption of alcohol during treatment with methocarbamol can increase the effect.

The effects of anticholinergics, such as atropine and some psychotropic drugs, may be potentiated by methocarbamol.

Methocarbamol may reduce the effect of pyridostigmine bromide. Therefore, methocarbamol should not be used by patients with myasthenia gravis, particularly those being treated with pyridostigmine.

4.6. Fertility, pregnancy and lactation

Pregnancy

There is no experience with the use of methocarbamol during pregnancy .There are no data from animal studies related to effects on pregnancy , embryonal/foetal development, parturition and postnatal development ( see section 5.3). the potential risk for humans is unknown. Therefore methocarbamol should not be used during pregnancy.

Breastfeeding

It is not known whether methocarbamol and/or its metabolites are excreted in human milk. Methocarbamol and/or its metabolites are excreted in the milk of lactating dogs Methocarbamol should therefore not be used during breastfeeding.

Fertility

No data are available on the influence of methocarbamol on human fertility.

4.7. Effects on ability to drive and use machines

Methocarbamol has moderate influence on the ability to drive and to use machines. Methocarbamol can cause dizziness or drowsiness, especially if other medicines that can also cause drowsiness are being taken at the same time..

Patients should be advised not to perform these activities if they experience dizziness or drowsiness.

4.8. Undesirable effects

The frequency information on side effects is based on the following categories (where it has been possible to obtain frequency data from the literature):

Very common ≥ 1/10

Common ≥ 1/100 to < 1/10

Uncommon ≥ 1/1,000 to < 1/100

Rare ≥ 1/10,000 to < 1/1,000

Very rare < 1/10,000

Not known The frequency cannot be estimated from the available data

The following adverse reactions have been reported with the use of methocarbamol:

System organ class

Frequency according to MedDRA convention

Rare

Very rare

Not known

Infections and infestations

Conjunctivitis

Immune system disorders

Anaphylactic reaction

Metabolism and nutrition disorders

Decreased appetite

Psychiatric disorders

Restlessness, anxiety, confusion

Nervous system disorders

Headache, dizziness, metallic taste

Syncope, nystagmus, drowsiness,, tremor, seizure

Somnolence, coordination disorder,

Hypoesthesia*,

Paresthesia*

Eye disorders

Visual impairment, double vision

Cardiac disorders

Bradycardia

Vascular disorders

Hypotension

Hot flush

Respiratory, thoracic and mediastinal disorders

Swelling of nasal mucosa

Gastrointestinal disorders

Nausea, vomiting

Nausea, diarrhoea

Skin and subcutaneous tissue disorders

Angioedema, rash, pruritus, urticaria

General disorders and administration site conditions

Fever

Fatigue

*Localized, transient sensory disturbance primarily affecting the head (e.g. face, scalp), the mouth region (e.g. lips, tongue) or the extremities (hands, fingers, feet)

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures and coma. One adult survived the deliberate ingestion of 22 to 30 grams of methocarbamol without serious toxicity. Another adult survived a dose of 30 to 50 grams. The principal symptom in both cases was extreme drowsiness. Treatment was symptomatic and recovery was uneventful. However, there have been cases of fatal overdose.

Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of haemodialysis in managing overdose is unknown.

💬 Ask about this leaflet

Ask anything about Methocarbamol 750 mg film-coated tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →